Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 29, 2007 (Three and Six Months)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors anywhere in the body. The company generates revenue through product sales, shared ownership programs, and service plans. As of December 31, 2007, 126 CyberKnife systems were installed globally.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2007 | 6 Months Ended Dec 31, 2007 | 6 Months Ended Dec 31, 2006 |
|---|---|---|---|
| Total Net Revenue | $52,038 | $100,684 | $59,118 |
| Gross Profit | $27,862 | $53,773 | $34,005 |
| Gross Margin | 53.5% | 53.4% | 57.5% |
| Net Income (Loss) | $2,343 | $4,608 | $(5,333) |
| EPS (Diluted) | $0.04 | $0.08 | $(0.33) |
| Cash and Equivalents (Balance Sheet) | $187,482 (as of Dec 31, 2007) | ||
| Net Cash Used in Operating Activities | $(15,245) (6 months 2007) | ||
| Backlog | $659.9 million (as of Dec 31, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 97% year-over-year for the three months ended Dec 31, 2007, and 70% for the six-month period. This was driven by an increase in CyberKnife system installations (12 units in Q4 2007 vs. 7 in Q4 2006) and a shift in service plan mix.
- Profitability: The company reported a net income of $2.3 million for the quarter and $4.6 million for the six months, a significant turnaround from a net loss of $7.3 million and $5.3 million, respectively, in the prior year periods.
- Margin Compression: Gross margin decreased to 53.5% (Q4) and 53.4% (6 months) from 55.8% and 57.5% in the prior year. Management attributed this to increased shipments through distributor channels and sales of shared ownership units, which typically carry lower margins.
- Operating Expenses: Selling, marketing, R&D, and G&A expenses increased in absolute dollars due to headcount growth and stock-based compensation, but decreased as a percentage of revenue due to revenue leverage.
- Interest Income: Interest and other income surged to $2.3 million (Q4) and $5.0 million (6 months) from $167k and $436k in the prior year, driven by higher cash balances from the IPO.
Guidance, Outlook, Risks, and Unusual Items
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting identified in the prior year audit, relating to segregation of duties and revenue recognition. Management is implementing remediation but concluded disclosure controls were not effective as of Dec 31, 2007.
- Revenue Recognition: A significant portion of revenue is deferred due to legacy multiyear service plans (Platinum/Gold) that require delivery of upgrades before revenue can be recognized. The company continues to transition to the "Diamond" plan which allows for earlier recognition.
- Stock Repurchases: The company initiated a $25 million stock repurchase program in August 2007. By Dec 31, 2007, it had repurchased 222,051 shares for $3.3 million. Additional repurchases of 569,100 shares occurred in early 2008.
- Risk Factors: Key risks include dependence on third-party payor reimbursement (Medicare rates), reliance on single-source suppliers for critical components, and the long sales/installation cycle (12-18 months) which causes quarterly volatility.
- Outlook: Management believes current cash resources are sufficient for at least the next 12 months. Future success depends on market acceptance of the CyberKnife system and the ability to convert backlog into recognized revenue.
Investor Verification Checklist
- Backlog Conversion: Verify the rate at which the $659.9 million backlog is being converted to revenue, specifically regarding legacy service plan upgrade obligations.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in internal controls to ensure future financial reporting accuracy and compliance with Section 404 of Sarbanes-Oxley.
- Reimbursement Rates: Track changes in Medicare and third-party payer reimbursement rates for CyberKnife procedures, as these directly impact customer purchasing decisions.
- Supplier Concentration: Assess the risk associated with single-source suppliers for critical components like the robotic manipulator and magnetron.
- Stock-Based Compensation: Review the impact of stock-based compensation on future earnings, noting $8.6 million was recognized in the first six months of fiscal 2008.